Technical Analysis for IMMU - Immunomedics, Inc.
|Grade||Last Price||% Change||Price Change|
IMMU closed down 2.08 percent on Friday, November 17, 2017, on 80 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.
|Weak or Absent||Up||Up||Up|
|See historical IMMU trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 17||50 DMA Support||Bullish||0.00%|
|Nov 17||NR7||Range Contraction||0.00%|
|Nov 17||Calm After Storm||Range Contraction||0.00%|
|Nov 16||Crossed Above 50 DMA||Bullish||-2.08%|
|Nov 16||Calm After Storm||Range Contraction||-2.08%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more IMMU news...
|52 Week High||14.48|
|52 Week Low||3.01|
|200-Day Moving Average||8.4402|
|50-Day Moving Average||11.6185|
|20-Day Moving Average||10.9815|
|10-Day Moving Average||10.956|
|Average True Range||0.9859|
|Chandelier Exit (Long, 3 ATRs )||9.8723|
|Chandelier Exit (Short, 3 ATRs )||12.6777|
|Upper Bollinger Band||12.206|
|Lower Bollinger Band||9.757|
|Percent B (%b)||0.81|
|MACD Signal Line||-0.1711|
|Market Cap||1.31 Billion|
|Num Shares||111 Million|
|Price-to-Earnings (P/E) Ratio||-7.99|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||12.55|
|Resistance 3 (R3)||12.56||12.31||12.41|
|Resistance 2 (R2)||12.31||12.11||12.30||12.37|
|Resistance 1 (R1)||12.03||11.98||11.91||12.02||12.32|
|Support 1 (S1)||11.50||11.58||11.38||11.49||11.18|
|Support 2 (S2)||11.25||11.45||11.24||11.13|
|Support 3 (S3)||10.97||11.25||11.09|
|Support 4 (S4)||10.96|